Janux Therapeutics Inc Ordinary Shares JANX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb
Trading Information
- Previous Close Price
- $17.63
- Day Range
- $12.43–17.95
- 52-Week Range
- $12.12–35.34
- Bid/Ask
- $13.00 / $13.14
- Shares Outstanding
- 61.18M
- Market Cap
- $780.11M
- Volume/Avg
- 252 / 835,872
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 114
- Website
- https://www.januxrx.com
Valuation
Metric | JANX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.86 |
Price/Sales | 34.36 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | JANX |
|---|---|
Quick Ratio | 17.56 |
Current Ratio | 17.69 |
Interest Coverage | — |
Quick Ratio
JANX
Profitability
Metric | JANX |
|---|---|
Return on Assets (Normalized) | −6.29% |
Return on Equity (Normalized) | −6.73% |
Return on Invested Capital (Normalized) | −10.70% |
Return on Assets
JANX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|P<L%gMP | LOCK|@n&Sj | $140B | |||
| Moderna Inc MRNA | LOCK|<vCY%c | LOCK|wzj | $109B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|n@yrh#h | LOCK|!L$> | $95B | |||
| argenx SE ADR ARGX | LOCK|W%Sy#@< | LOCK|Nf& | $60B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|KckYV@z | LOCK|l<^ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|@&#%>SW# | LOCK|sxrX | $31B | |||
| Incyte Corp INCY | LOCK|?%$@>$ | LOCK|tQ | $25B | |||
| BioNTech SE ADR BNTX | LOCK|w@@Rk^$ | LOCK|$N! | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|YlBn!qk | LOCK|dLh$ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|BB$p>xm | LOCK|pfd | $16B |
United States